about
Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseasesEzetimibe for primary hypercholesterolemiaEzetimibe for primary hypercholesterolemiaAntianginal actions of beta-adrenoceptor antagonistsCoagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparinTolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis.Therapy of unstable angina with the low molecular weight heparins.Value and limitations of ambulatory ECG monitoring for assessment of myocardial ischemia.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?Perioperative myocardial infarction in noncardiac surgery: the diagnostic and prognostic role of cardiac troponins.Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris.Cultural aspects of adjustment to coronary heart disease in Chinese-Australians: a review of the literature.A genetic fuzzy system for unstable angina risk assessment.Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndromeThe effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.Circulating miRNAs: novel biomarkers of acute coronary syndrome?Serum Metabolomics Profiling to Identify Biomarkers for Unstable Angina.Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.Assessment of clopidogrel on the left ventricular ejection fraction in acute myocardial infarction.The challenge of traditional Chinese medicines for allopathic practitioners.AIDS-defining opportunistic illnesses in the HAART era in New York City.Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design.Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1b/Pl) and alpha2(beta)1 (alpha807TT) with premature myocardial infarction.Identification of biomarkers for unstable angina by plasma metabolomic profiling.Impact of acute coronary syndrome classification and procedural technique on clinical outcomes in patients with coronary bifurcation lesions treated with drug-eluting stents.The association between hyperglycaemia and elevated troponin levels on mortality in acute coronary syndromes.
P2860
Q21296645-23E67F68-B3F9-42CD-8242-724059F83D08Q24187681-9651FFAC-0929-4EFC-8A8B-0D26F73A85FFQ24244704-2E054E48-2F9A-42EF-8660-5FCEE081FD78Q24682302-897CA56E-7AC6-4E8E-AA59-CA5E84D5AFBAQ28208874-D9BF3921-8CCF-47E3-BE20-0F75E2F77185Q33414284-12C9C29C-D6DB-4D34-AE36-4CAE40A13692Q34158934-6D9E0BC6-4E74-43BC-A1FA-5D602DC89EE1Q34315285-8A5AC89F-CB82-4936-9AE8-3C605C68ACC9Q34445660-7F829915-64A3-471D-A74C-C9B9F8EDAC88Q34482530-83A6AA3E-0BF0-4F68-93FE-274CEC5F3A47Q34696254-56730D18-4D45-4C5C-B6C2-8CAE2E69ABA3Q34704614-865DE57D-2B8D-40CD-A3A4-0A0E386A7FFFQ34760545-523CF326-8431-4FCA-90DC-5C2028139E05Q35096829-BE2957D7-7CA4-4931-B63C-F9FD2284FD3FQ35944733-A1092094-7F00-4583-B36F-5236844A64E7Q36841959-5DA8642D-3BA2-41F3-8F9E-6418B0D09097Q37240345-7F53122A-C1AD-46A5-9C85-2749FD6753CCQ38095110-E4DAD970-738E-4726-9816-05C685A41284Q42215285-F44CDEC7-AD2B-461D-BDED-C7F43E781B3DQ42635425-8F71F731-EC35-41B5-9842-F04B43AF9F36Q42715655-0576D2F3-8994-45CB-819A-0447CEEF4363Q43255376-F0FA58E6-0058-4A20-B6E8-68321054C4E9Q44766188-1E2403D3-6098-45A7-A27B-53E5B35B1F42Q45385963-A7708D79-6208-4234-B821-45782EC9CC8CQ46359254-3BBEDA05-98C3-4501-A624-73520821C28DQ46566213-62F90BDC-0891-4F31-B5B0-262EB7BBEDDCQ46959632-6E8A793B-EBA1-439F-881E-EFC5389B4C4DQ47610679-CD61AF8A-766D-4F66-933C-E732025F74A4Q52854991-574B499F-3195-418E-A536-C2198C8807E1
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Unstable angina pectoris
@ast
Unstable angina pectoris
@en
Unstable angina pectoris
@nl
type
label
Unstable angina pectoris
@ast
Unstable angina pectoris
@en
Unstable angina pectoris
@nl
prefLabel
Unstable angina pectoris
@ast
Unstable angina pectoris
@en
Unstable angina pectoris
@nl
P2093
P1476
Unstable angina pectoris
@en
P2093
J B Braunstein
Y Yeghiazarians
P304
P356
10.1056/NEJM200001133420207
P407
P577
2000-01-13T00:00:00Z